

+35

UBS Future of Humans USD F-acc

140

Fund Fact Sheet

UBS Funds for discretionary mandates > UBS Equity Funds


Fund description

- An actively managed multi-manager global equity fund that invests in companies exposed to the global trends toward an aging population, the growth in population and increasing urbanization.
- These aspects can comprise any sectors. • countries and company capitalisations in order to benefit from disruptive developments in society, resources and technology, with a focus on longevity, education, healthcare and consumer preferences.

135	
155	
130	
150	

Rebased to 100 on the basis of month-end data

Performance (basis USD, net of fees)¹



Fund performance net of fees (left-hand scale)

..... Index performance (left-hand scale)

Past performance is not a reliable indicator of future results.

Name of fund	Multi Manager Access II - Future of
	Humans
Share class	Multi Manager Access II - Future of
	Humans USD F-acc
ISIN	LU2213664688
Securities no.	56 358 950
Bloomberg	MUFOHUF LX
Currency of fund / share	e class USD/USD
Launch date	19.10.2020
Issue/redemption	daily
Swing pricing	yes
Accounting year end	31 July
Benchmark	MSCI ACWI Net Total Return index
Distribution	Reinvestment
Management fee p.a.	0.65%
Ongoing charges p.a.1	0.80%
Name of the	UBS Fund Management
Management Company	(Luxembourg) S.A.,
	Luxembourg
Fund domicile	Luxembourg

in % 2017 2018 2019 2020 2021 LTD³ Ø p.a. 2 1 year YTD² years Fund (USD) n.a. n.a. n.a. n.a. 5.45 14.57 n.a n.a. Ref. Index⁴ 11.12 24.40 n.a. n.a. n.a. n.a. n.a. n.a

The performance shown does not take account of any commissions, entry or exit charges.

These figures refer to the past. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Source for all data and charts (if not indicated otherwise): UBS Asset Management. YTD: year-to-date (since beginning of the year) LTD: launch-to-date Reference Index in currency of share class (without costs)

4

Fund statistics

З

Net asset value (USD, 30.09.2021)	114.57
Last 12 months (USD) – high	122.11
- low	93.98
Total fund assets (USD m)	1 037.43
Share class assets (USD m)	686.26

1 as at 13.09.2021

	3 years	5 years
Beta	n.a.	n.a.
Volatility ¹		
– Fund	n.a.	n.a.
– Benchmark	n.a.	n.a.
Sharpe ratio	n.a.	n.a.
Risk free rate	n.a.	n.a.

1 Annualised standard deviation

For more information

Internet: www.ubs.com/luxembourgfunds Contact your client advisor

UBS Future of Humans USD F-acc

Sector exposure (%)

	Fund	Index
Health Care	42.36	11.69
Consumer Discretionary	25.17	12.44
Communication Services	8.30	9.27
Information Technology	8.24	22.33
Financials	6.77	14.38
Real estate	3.24	2.62
Industrials	2.07	9.67
Consumer Staples	1.79	6.77
Materials	1.36	4.66
Others	0.70	6.17

10 largest equity positions (%)

	Fund	Index
Abbott Laboratories	2.55	0.32
Medtronic PLC	2.05	0.26
Amazon.com Inc	1.74	2.27
Roche Holding AG	1.71	0.39
Novo Nordisk A/S	1.69	0.25
Paycom Software Inc	1.56	0.04
Booking Holdings Inc	1.52	0.15
Moderna Inc	1.50	0.20
AstraZeneca PLC	1.50	0.28
UnitedHealth Group Inc	1.49	0.56

Market exposure (%)

	Fund	Deviation from	index
United States	59.23	-0.3	
United Kingdom	5.87		+2.2
Switzerland	5.65		+3.2
China	5.33		+1.3
Japan	4.23	-2.0	
Ireland	2.82		+2.6

Benefits

Benefit from developments driven by the meta themes education, healthcare and changing consumer preferences. Harnesses the dedicated capabilities of leading thematic portfolio managers, most of whom are not accessible via public funds.

A focus on attractively valued companies with strong links to the respective themes.

The structure allows for the addition/removal of managers as well as portfolio optimization.

	Fund	Deviation from index
Germany	2.72	+0.4
Denmark	2.45	+1.8
Hong Kong	2.37	+ 1.6
France	1.29	-1.6
Others	8.04	-9.2

Risks

A new fund with no track record, notwithstanding the investment history of the portfolio managers. An equity fund with exposure to small, growing and innovative companies which can result in significant fluctuations in value, particularly in the short term.

The thematic focus may lead to concentrations in a specific sector or style.

The performance of actively managed funds may deviate significantly from the referenced index.

The fund can use derivatives, which may result in additional counterparty and liquidity risks.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at www.ubs.com/amglossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, *clo* UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 of Regulation (EU) 2019/2088. Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. The fund document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds and opinions or take a negative inpact on performance. If the currency of a financial product of financial protucties or related financial instruments. Past performance is not a reliable indicator of future results. The performance. If the currency of a financial product of the secirities or related financial instruments. Past performance is not a reliable indicator of performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease